May 14th 2025
Telisotuzumab vedotin (Teliso-V) gained FDA approval as a targeted therapy for patients with advanced non–small cell lung cancer (NSCLC) with high c-Met overexpression, offering new hope.
Watch the series now!
New CDC Report Provides Update on Incidence Rates of Pediatric ALL
First Anticancer Biosimilar Treatment Approved for Multiple Indications
Bringing Drugs to Market Costs Less Than Previously Thought, Study Finds
MACRA Survey Finds Oncology Physicians Unprepared for Payment Changes
Companies Continue to Face Challenges With Developing CAR-T Treatment
Healthy, but Still Hurting: Challenges of Cancer Survivorship